Article
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
Pharmacogenetics and genomics - 1 Jan 2012
Birdwell Kelly A, Grady Ben, Choi Leena, Xu Hua, Bian Aihua, Denny Josh C, Jiang Min, Vranic Gayle, Basford Melissa, Cowan James D, Richardson Danielle M, Robinson Melanie P, Ikizler Talat Alp, Ritchie Marylyn D, Stein Charles Michael, Haas David W
Abstract excerpt
OBJECTIVE: Tacrolimus, an immunosuppressive drug widely prescribed in kidney transplantation, requires therapeutic drug monitoring due to its marked interindividual pharmacokinetic variability and narrow therapeutic index. Previous studies have established that CYP3A5 rs776746 is associated with tacrolimus clearance, blood concentration, and dose requirement. The importance of other drug absorption, distribution,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
